KEAP1 and non-small cell lung carcinoma: To examine the influence of KEAP1/NRF2 mutations on NSCLC response to β-lapachone treatment, we assessed the cytotoxic efficacy of β-lapachone in a panel of sixteen NSCLC cell lines, seven of which harbor characterized inactivating mutations of KEAP1 (Fig. 1C, S1A). In line with the mRNA data of LuSC and LuAD patients, KEAP1MUT cell lines displayed uniformly high NQO1 protein levels, while protein levels of NQO1 in KEAP1WT cells were highly variable.